Cargando…

Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients

This is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significa...

Descripción completa

Detalles Bibliográficos
Autores principales: Aquino, Adriano, Alexandrino, Guilherme L., Guest, Paul C., Augusto, Fabio, Gomes, Alexandre F., Murgu, Michael, Steiner, Johann, Martins-de-Souza, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982405/
https://www.ncbi.nlm.nih.gov/pubmed/29887809
http://dx.doi.org/10.3389/fpsyt.2018.00209
_version_ 1783328234185687040
author Aquino, Adriano
Alexandrino, Guilherme L.
Guest, Paul C.
Augusto, Fabio
Gomes, Alexandre F.
Murgu, Michael
Steiner, Johann
Martins-de-Souza, Daniel
author_facet Aquino, Adriano
Alexandrino, Guilherme L.
Guest, Paul C.
Augusto, Fabio
Gomes, Alexandre F.
Murgu, Michael
Steiner, Johann
Martins-de-Souza, Daniel
author_sort Aquino, Adriano
collection PubMed
description This is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significant improvement in positive and negative symptoms for 34 patients with little or no improvement for 20 patients. In addition, 37 patients showed an increase in body mass index after the 6 week treatment period, consistent with effects on metabolism and the association of such effects with symptom improvement. Profiling of plasma samples taken prior to therapy using liquid chromatography tandem mass spectrometry (LC-MS/MS) resulted in identification of 38, 10, and 52 compounds associated with the olanzapine, risperidone, and quetiapine treatment groups, which could be used to distinguish responders from non-responders. Limitations include the retroactive active nature of the study and the small sample size. Further investigations with larger sample sets could lead to the development of a molecular test that could be used to help psychiatrists determine the best treatment options for each patient.
format Online
Article
Text
id pubmed-5982405
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59824052018-06-08 Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients Aquino, Adriano Alexandrino, Guilherme L. Guest, Paul C. Augusto, Fabio Gomes, Alexandre F. Murgu, Michael Steiner, Johann Martins-de-Souza, Daniel Front Psychiatry Psychiatry This is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significant improvement in positive and negative symptoms for 34 patients with little or no improvement for 20 patients. In addition, 37 patients showed an increase in body mass index after the 6 week treatment period, consistent with effects on metabolism and the association of such effects with symptom improvement. Profiling of plasma samples taken prior to therapy using liquid chromatography tandem mass spectrometry (LC-MS/MS) resulted in identification of 38, 10, and 52 compounds associated with the olanzapine, risperidone, and quetiapine treatment groups, which could be used to distinguish responders from non-responders. Limitations include the retroactive active nature of the study and the small sample size. Further investigations with larger sample sets could lead to the development of a molecular test that could be used to help psychiatrists determine the best treatment options for each patient. Frontiers Media S.A. 2018-05-25 /pmc/articles/PMC5982405/ /pubmed/29887809 http://dx.doi.org/10.3389/fpsyt.2018.00209 Text en Copyright © 2018 Aquino, Alexandrino, Guest, Augusto, Gomes, Murgu, Steiner and Martins-de-Souza. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Aquino, Adriano
Alexandrino, Guilherme L.
Guest, Paul C.
Augusto, Fabio
Gomes, Alexandre F.
Murgu, Michael
Steiner, Johann
Martins-de-Souza, Daniel
Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
title Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
title_full Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
title_fullStr Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
title_full_unstemmed Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
title_short Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients
title_sort blood-based lipidomics approach to evaluate biomarkers associated with response to olanzapine, risperidone, and quetiapine treatment in schizophrenia patients
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982405/
https://www.ncbi.nlm.nih.gov/pubmed/29887809
http://dx.doi.org/10.3389/fpsyt.2018.00209
work_keys_str_mv AT aquinoadriano bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients
AT alexandrinoguilhermel bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients
AT guestpaulc bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients
AT augustofabio bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients
AT gomesalexandref bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients
AT murgumichael bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients
AT steinerjohann bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients
AT martinsdesouzadaniel bloodbasedlipidomicsapproachtoevaluatebiomarkersassociatedwithresponsetoolanzapinerisperidoneandquetiapinetreatmentinschizophreniapatients